Japan Airlines Co., Ltd. (JAL) announces the launch of “J SOLUTIONS PHARMA CELLS,” a specialised cell transport service designed to support advancements in regenerative medicine, a rapidly evolving and critical medical field.
The rapid growth of regenerative medicine has led to increasing demand for highly specialised cell transport solutions. Leveraging its extensive expertise in pharmaceutical logistics, JAL is committed to driving progress in the medical field by addressing these emerging needs.
Starting from July 7, 2025, “J SOLUTIONS PHARMA CELLS,” a dedicated service tailored to meet the requirements driven by advancements in regenerative medicine technology, will be launched. Through this service, JAL seeks to contribute to a world where groundbreaking medical treatments for previously challenging diseases—including Parkinson’s disease—are widely and globally accessible, supported by remarkable advances in regenerative medicine, such as iPS cell technologies.
Cells intended for therapeutic applications have significantly different handling and transport requirements compared to conventional pharmaceuticals. These cells demand rapid, secure, and dependable handling. “J SOLUTIONS PHARMA CELLS” meets these demands with an innovative, customizable transport service that prioritizes pharmaceutical-grade care and fast responsiveness.
Key features of “J SOLUTIONS PHARMA CELLS”
Point 1: Specialised Cell Transport Services
Expertise in handling live cells, cryopreserved cells, and cell-derived products, ensuring safe and reliable transportation.
Point 2: Priority and Speed
Allows rapid transit, with submissions accepted just 90 minutes before departure and deliveries completed within 90 minutes after arrival. This service is currently available at Narita, Haneda, and Kansai Airports, as well as 10 key hubs globally, with plans for further expansion.
Point 3: Risk Mitigation
Careful cargo transportation between the aircraft and the cargo warehouse is handled separately from other shipments to effectively minimise the risk of contamination.
This service builds on JAL’s extensive experience and technological expertise in handling high-value pharmaceutical cargo, which has been a key strategic focus. By seamlessly combining the speed of air transport with adherence to stringent quality standards, this solution addresses the unique demands of the regenerative medicine sector.
JAL has established a robust foundation for high-quality pharmaceutical logistics services, achieving IATA’s CEIV Pharma certification and equipping Narita and Kansai Airports with dedicated pharmaceutical storage facilities. These efforts highlight JAL’s ability to support both the technological and operational aspects of this specialized logistics field.
According to Japan’s Cabinet Office, the market for regenerative medicine is expected to expand more than tenfold over the next decade. As the demand for specialized transport services grows, these societal challenges are seen as opportunities to create new value in emerging business areas.
Through “J SOLUTIONS PHARMA CELLS,” JAL is committed to advancing regenerative medicine and addressing global medical challenges, ultimately contributing to societal well-being worldwide.
